keyword
MENU ▼
Read by QxMD icon Read
search

Chronic idiopathic urticaria

keyword
https://www.readbyqxmd.com/read/29132956/the-xtend-ciu-study-long-term-use-of-omalizumab-in-chronic-idiopathic-urticaria
#1
Marcus Maurer, Allen Kaplan, Karin Rosén, Michael Holden, Ahmar Iqbal, Benjamin L Trzaskoma, Ming Yang, Thomas B Casale
These data support omalizumab safety and efficacy in patients with antihistamine-resistant CIU/CSU to 48 weeks and provide evidence of omalizumab re-treatment efficacy and safety.
November 10, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29064325/real-world-treatment-patterns-and-outcomes-of-omalizumab-use-in-patients-with-chronic-idiopathic-urticaria
#2
Liya Wang, Xuehua Ke, Abhishek Kavati, Debra Wertz, Qing Huang, Vincent J Willey, Judith J Stephenson, Benjamin Ortiz, Brandee Paknis, Jonathan A Bernstein, Lisa A Beck
OBJECTIVE: To examine treatment patterns, treatment response, and demographic and clinical characteristics of patients with chronic idiopathic urticaria (CIU) newly initiated on omalizumab therapy in real-world practice in the US. METHODS: This retrospective observational cohort study used US claims data from the HealthCore Integrated Research Database (HIRD(®)) augmented with medical record data to identify CIU patients newly-treated with omalizumab (≥4 omalizumab claims within 6 months of initial claim; index date = first omalizumab claim date) between March 21, 2014 and October 31, 2015 and with ≥6 months pre- and ≥12 months post-index health plan eligibility...
November 10, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29037993/omalizumab-response-in-patients-with-chronic-idiopathic-urticaria-insights-from-the-xtend-ciu-study
#3
Thomas B Casale, Patrick H Win, Jonathan A Bernstein, Karin Rosén, Michael Holden, Ahmar Iqbal, Benjamin L Trzaskoma, Ming Yang, Evgeniya N Antonova, Thomas Murphy, Mark D Scarupa, Howard Sofen, Allen Kaplan
No abstract text is available yet for this article.
October 13, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28888844/recurrence-of-chronic-urticaria-incidence-and-associated-factors
#4
Julie K Kim, Daniel Har, L Steven Brown, David A Khan
BACKGROUND: Chronic urticaria (CU) is urticaria that has been present continuously or intermittently for at least 6 weeks. Although the prevalence and characteristics of CU are well established, little is known about recurrent CU (RCU). OBJECTIVES: We sought to establish a definition, determine the frequency, and evaluate risk factors for RCU. METHODS: A retrospective chart review of adult patients with CU evaluated at the University of Texas Southwestern allergy and immunology clinic was performed...
September 6, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28852410/management-of-chronic-spontaneous-urticaria-csu-a-treat-to-target-approach-using-a-patient-reported-outcome
#5
Hermenio Lima, Melinda Gooderham, Jan Dutz, Charles Lynde, Hugo Chapdelaine, Anne Ellis, Martin Gilbert, Vincent Ho, Kim Papp, Yves Poulin, Gordon Sussman
BACKGROUND: Treat-to-target therapy approaches are established for chronic diseases such as diabetes, hypertension, and more recently rheumatoid arthritis, resulting in improved patient outcomes. These approaches do not use patient reported outcomes (PRO) as targets of therapy. Chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria (CIU), is defined as recurrent urticaria of known and unknown cause, lasting more than 6 weeks. Treatment of CSU can be challenging...
2017: Allergy, Asthma, and Clinical Immunology
https://www.readbyqxmd.com/read/28819778/impact-of-jumihaidokuto-shi-wei-bai-du-tang-on-treatment-of-chronic-spontaneous-urticaria-a-randomized-controlled-study
#6
Hiroyuki Murota, Hiroaki Azukizawa, Ichiro Katayama
OBJECTIVE: To study the effect of Jumihaidokuto (Shi-Wei-Bai-Du-Tang, ) in the management of chronic spontaneous urticaria. METHODS: A randomized two-arm, parallel group study was conducted to compare the effect of Jumihaidokuto (6 g daily) with a control for 8 weeks. Concomitant therapy (e.g., antihistamines) was continued. Twenty-one subjects with severe chronic urticaria were enrolled in this study. The primary treatment outcome was the severity score proposed by the Japanese Dermatological Association...
August 17, 2017: Chinese Journal of Integrative Medicine
https://www.readbyqxmd.com/read/28714496/clinical-outcome-of-autologous-serum-therapy-in-chronic-idiopathic-urticaria
#7
D Karn, S Kc
BACKGROUND: Quality of life in chronic idiopathic urticaria is hampered as efficacy of H1-antihistamines is limited. Autologous serum containing tolerance-generating anti-idiotype antibodies is a novel and cost-effective therapy. This study was conducted to evaluate the efficacy of autologous serum therapy (AST) among chronic urticaria patients with autologous skin prick test positive and negative status. METHODS: Untreated 102 patients of chronic urticaria were enrolled in a non-randomized interventional study...
January 2017: Journal of Nepal Health Research Council
https://www.readbyqxmd.com/read/28702966/possible-role-of-helicobacter-pylori-in-diseases-of-dermatological-interest
#8
C Guarneri, J Lotti, M Fioranelli, M G Roccia, T Lotti, F Guarneri
Helicobacter pylori is a gram-negative, flagellate, microaerophilic bacterium identified for the first time about 30 years ago, as a pathogenic factor of gastritis and peptic ulcer. Soon after, it was linked to several gastrointestinal and extra-gastrointestinal diseases (hematological, cardiovascular, neurological, pulmonary and ocular diseases, obesity, diabetes mellitus, growth retardation and extragastric MALT lymphoma). Association and possible cause-effect correlation with H. pylori infection were suggested in diseases of dermatological interest such as chronic urticaria, rosacea, Henoch-Schoenleins purpura, idiopathic thrombocytopenic purpura, cutaneous and oral lichen planus, atopic dermatitis, recurrent aphthous stomatitis, systemic sclerosis, psoriasis, Sjögrens syndrome, Behçet's disease, pruritus, alopecia areata, primary cutaneous marginal zone B-cell lymphomas, vitiligo, chronic prurigo, multiformis, prurigo nodularis, leukocytoclastic vasculitis, prurigo pigmentosa, eczema nummulare, primary cutaneous MALT-type lymphoma, sublamina densa-type linear IgA bullous dermatosis, Sweet's syndrome, cutaneous T-cell pseudolymphoma and pemphigus vulgaris...
April 2017: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/28686766/evaluation-of-patch-test-reactivities-in-patients-with-chronic-idiopathic-urticaria
#9
Khalid M AlGhamdi, Huma Khurrum, Mohamed O Gad Al Rab
Chronic idiopathic urticaria (CIU) is one of the mysteries of dermatology. An association between spontaneous CIU and contact allergy sensitization is possible. In this study, we aimed to test the hypothesis that contact allergy might play a role in disease in CIU patients. Furthermore, we examined if patch testing should be routinely performed in patients with chronic urticaria (CU). Ultimately, we concluded that patch testing should be included among the diagnostic procedures for CU.
June 2017: Cutis; Cutaneous Medicine for the Practitioner
https://www.readbyqxmd.com/read/28671445/acute-and-chronic-urticaria-evaluation-and-treatment
#10
REVIEW
Paul Schaefer
Urticaria commonly presents with intensely pruritic wheals, sometimes with edema of the subcutaneous or interstitial tissue. It has a lifetime prevalence of about 20%. Although often self-limited and benign, it can cause significant discomfort, continue for months to years, and uncommonly represent a serious systemic disease or life-threatening allergic reaction. Urticaria is caused by immunoglobulin E- and non-immunoglobulin E-mediated release of histamine and other inflammatory mediators from mast cells and basophils...
June 1, 2017: American Family Physician
https://www.readbyqxmd.com/read/28583230/differential-expression-of-micrornas-and-their-possible-roles-in-patients-with-chronic-idiopathic-urticaria-and-active-hives
#11
Ching-Kow E Lin, John S Kaptein, Javed Sheikh
BACKGROUND: Chronic idiopathic urticaria (CIU) is a complicated skin disease with unknown pathophysiology. MicroRNAs (miRNA) have been shown to be active in cellular regulation. The goal of this pilot study was to examine whether miRNAs may be involved in the regulation of CIU or as biomarkers for CIU. METHODS: Four groups of three patients each were selected: patients with either active hives or no hives and with positive or negative chronic urticaria (CU) index results...
June 1, 2017: Allergy & Rhinology
https://www.readbyqxmd.com/read/28573683/omalizumab-substantially-improves-dermatology-related-quality-of-life-in-patients-with-chronic-spontaneous-urticaria
#12
A Y Finlay, A P Kaplan, L A Beck, E N Antonova, M-M Balp, J Zazzali, S Khalil, M Maurer
BACKGROUND: Chronic spontaneous/idiopathic urticaria (CSU/CIU) has substantial detrimental effects on health-related quality of life (HRQoL) with an effect comparable to or worse than many other skin diseases. OBJECTIVE: To assess the effect of omalizumab on CSU patients' HRQoL, measured by the Dermatology Life Quality Index (DLQI) in three phase III studies ASTERIA I, ASTERIA II and GLACIAL. METHODS: A post hoc analysis examined changes in DLQI scores, distribution of patients across DLQI bands and the proportion reaching minimal clinically important difference (MCID) following omalizumab vs...
October 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28511822/posttraumatic-stress-disorder-ptsd-and-the-dermatology-patient
#13
Madhulika A Gupta, Patricia Jarosz, Aditya K Gupta
Dermatologic symptoms can be associated with posttraumatic stress disorder (PTSD) in several situations: (1) as features of some core PTSD symptoms, such as intrusion symptoms manifesting as cutaneous sensory flashbacks, as autonomic arousal manifesting as night sweats and idiopathic urticaria, and as dissociation manifesting as numbness and dermatitis artefacta; (2) the cutaneous psychosomatic effects of emotional and physical neglect and sexual abuse (eg, infantile eczema, cutaneous self-injury, and body-focused repetitive behaviors such as trichotillomania and skin picking disorder) and eating disorders, which can have dermatologic effects; (3) the direct effect of physical or sexual abuse or catastrophic life events (eg, earthquakes) on the skin; and (4) as a result of significant alterations in hypothalamic-pituitary-adrenal and sympatho-adrenal medullary axes, which can affect neuroendocrine and immune functions, and can lead to exacerbations of stress-reactive inflammatory dermatoses such as psoriasis, chronic urticaria, and atopic dermatitis...
May 2017: Clinics in Dermatology
https://www.readbyqxmd.com/read/28452298/corticosteroid-related-toxicity-in-patients-with-chronic-idiopathic-urticaria-chronic-spontaneous-urticaria
#14
Dennis Ledford, Michael S Broder, Evgeniya Antonova, Theodore A Omachi, Eunice Chang, Allan Luskin
BACKGROUND: Treatments for patients with chronic idiopathic urticaria (CIU)-chronic spontaneous urticaria (CSU) who were unresponsive to antihistamines include oral corticosteroids (OCS). Risks of OCS-related side effects in these patients have not been described quantitatively. OBJECTIVE: To investigate the relationship between OCS use and the risk of developing side effects possibly attributable to OCS and associated health care costs in privately insured patients with CIU/CSU...
November 1, 2016: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/28452145/how-to-manage-chronic-urticaria-beyond-guidelines-a-practical-algorithm
#15
REVIEW
K Rutkowski, C E H Grattan
Chronic urticaria (CU) is a disease characterized by pruritic weals, angio-oedema or both occurring for at least 6 weeks. It encompasses spontaneous and inducible urticarias. The national and international guidelines outline the principles of treatment. Omalizumab, an anti-immunoglobulin E monoclonal antibody, has transformed the management of many severe and treatment-refractory patients. However, current UK guidance on its use does not address the needs of those with less severe disease, inducible urticarias, idiopathic histaminergic angio-oedema without weals as a presentation of CU and omalizumab non-responders...
June 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28390587/clinical-features-of-adolescents-with-chronic-idiopathic-or-spontaneous-urticaria-review-of-omalizumab-clinical-trials
#16
REVIEW
Stanley Goldstein, Susan Gabriel, Farid Kianifard, Benjamin Ortiz, David P Skoner
BACKGROUND: Adults and adolescents were included in 3 phase 3 omalizumab trials in chronic idiopathic urticaria (CIU): ASTERIA I, ASTERIA II, and GLACIAL. OBJECTIVE: To describe the baseline clinical profile of adolescent patients with CIU enrolled in the omalizumab trials to add to the limited literature available on CIU in this population. METHODS: Data for patient demographics, baseline clinical disease characteristics, medical history, and previous CIU medication information (not efficacy assessments) from phase 3 omalizumab trials were pooled and descriptive statistical analyses performed for adolescent (12 to <18 years old) and adult (≥18 years old) subgroups...
April 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/28366435/efficacy-and-safety-of-omalizumab-in-japanese-and-korean-patients-with-refractory-chronic-spontaneous-urticaria
#17
Michihiro Hide, Hae-Sim Park, Atsuyuki Igarashi, Young-Min Ye, Tae-Bum Kim, Akiko Yagami, Jooyoung Roh, Jae-Hyun Lee, Yuko Chinuki, Sang Woong Youn, Soo-Keol Lee, Naoko Inomata, Jeong-Hee Choi, Atsushi Fukunaga, Junyi Wang, Soichiro Matsushima, Steve Greenberg, Sam Khalil
BACKGROUND: Many patients with chronic spontaneous/idiopathic urticaria (CSU/CIU) do not respond adequately to treatment with non-sedating H1 antihistamines (H1AH). There are limited studies on use of omalizumab as add-on therapy for treatment of CSU in an Asian population. OBJECTIVE: The POLARIS study (NCT02329223), representing the first randomized, double-blind, placebo-controlled phase III trial of omalizumab for CSU in an Eastern Asian population, evaluated efficacy and safety of omalizumab as add-on therapy for treatment of CSU...
March 21, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28302451/chronic-idiopathic-urticaria-systemic-complaints-and-their-relationship-with-disease-and-immune-measures
#18
Judy C Doong, Kris Chichester, Eric T Oliver, Lawrence B Schwartz, Sarbjit S Saini
BACKGROUND: Patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria sometimes report systemic complaints (SCs). OBJECTIVE: We sought to determine the frequency and characteristics of SCs among patients with CIU, as well as the association of SCs with disease measures, basophil histamine release, and serum tryptase. METHODS: Adult patients with CIU were recruited from a university allergy clinic. Patients completed a disease symptom survey and underwent blood sampling for subsequent basophil histamine release and serum tryptase measurement...
September 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28299827/factors-linked-to-disease-severity-and-time-to-remission-in-patients-with-chronic-spontaneous-urticaria
#19
REVIEW
M Sánchez-Borges, F Caballero-Fonseca, A Capriles-Hulett, L González-Aveledo, M Maurer
Biomarkers useful for the evaluation and management of patients with chronic spontaneous urticaria (CSU) are not currently available. A review of various clinical and laboratory markers that have been studied to assess their value for determining the severity or predicting the evolution of disease in adult patients with CSU was carried out. A search of the medical literature on PubMed and MEDLINE including the terms urticaria, chronic urticaria, chronic idiopathic urticaria, CSU, severity, prognosis and treatment was performed...
June 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28295198/analysis-of-disease-activity-categories-in-chronic-spontaneous-idiopathic-urticaria
#20
D Stull, D McBride, H Tian, A Gimenez Arnau, M Maurer, A Marsland, M-M Balp, S Khalil, C Grattan
BACKGROUND: Measurement of disease activity guides treatment of chronic spontaneous urticaria (CSU). A weekly Urticaria Activity Score - here, the average of twice-daily patient assessment of itch and hives scores summed over 1 week (UAS7TD ) - measures severity from 0 to 42. Insufficient evidence exists on whether disease activity states, defined by categorical UAS7TD scores, correlate with other patient-reported outcomes and treatment response. OBJECTIVES: To evaluate and compare categorical UAS7TD scores with selected measures of disease-related quality of life and impact...
October 2017: British Journal of Dermatology
keyword
keyword
12612
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"